The use is claimed of opioid peptides with a novel structure, which in addition to the pharmacophore contain structural elements that interact with neurotensisn receptors. Due to the synergistic interaction with the additional element, an augmented analgesic activity is obtained, capable of being used for an extended period due to decreased drug tolerance induction. These compounds may be of particular use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatoid, gout, neurodegeneration, post-operative or post-accidental lesions, or oncogenic lesions.